Wuhan Xirui Pharmaceutical Technology

Wuhan Xirui Pharmaceutical Technology Co., Ltd. is an innovative biopharmaceutical company based in Wuhan, China, specializing in the discovery and development of small molecule therapeutics. The company focuses on diverse therapeutic areas, including pain management, neurological disorders, cardiovascular diseases, and infectious diseases. Wuhan Xirui has advanced its lead candidate, BX-2501, into the IND stage with a clinical trial application accepted by China's Center for Drug Evaluation (CDE). Its preclinical research programs include the development of novel sodium channel protein type 10 subunit alpha (Nav1.8) modulators for pain and soluble epoxide hydrolase inhibitors for metabolic and cardiovascular conditions. Additionally, the company is developing amphotericin B amide derivatives as potential treatments for invasive fungal infections. Operating from the Optical Valley International Biomedical Enterprise Acceleration zone, Wuhan Xirui integrates drug discovery, quality management, and regulatory compliance to advance its pipeline.